The Board meets at least four times per year for formal meetings. It approves financial statements, dividends and significant changes in accounting practices and key commercial matters, such as decisions to be taken on whether to take forward or to cancel a material collaboration project or commercial agreement.

The Board has established three subcommittees with formally delegated duties and responsibilities, as summarized below:

Chair
Member
Chairman of the board
Financial expert
The Audit Committee’s principal functions include ensuring that appropriate systems of accounting and financial controls are in place, monitoring the integrity of the Group’s financial statements, reviewing the effectiveness of the accounting and internal control systems, reviewing reports from the Group’s auditors relating to accounting and internal controls, and reviewing the interim and annual results and reports to shareholders, in all cases having due regard to the interests of shareholders.
Audit Committee Position

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.
Chair

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.
Member

Audit Committee Terms of Reference

 Download
The Remuneration Committee is responsible for determining and agreeing with the Board the framework for the remuneration packages for each of the Executive Directors (the remuneration of the Non-Executive Directors is determined by the Board). The Remuneration Committee considers all aspects of the Executive Directors’ remuneration, including pensions, bonus arrangements, benefits, incentive payments and share option awards, and the policy for, and scope of, any termination payments. No Director is involved in discussions relating to their own remuneration.
Remuneration Committee Position

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.
Chair

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.
Member

Remuneration Committee Terms of Reference

 Download
The Nomination Committee is responsible for reviewing the structure, size and composition of the Board based upon the skills, knowledge and experience required to ensure that it continues to operate effectively. The Nomination Committee also identifies and nominates suitable candidates to join the Board when vacancies arise and makes recommendations to the Board for the reappointment of any Non-Executive Directors.
Nomination Committee Position

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.
Member

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.
Member

Nomination Committee Terms of Reference

 Download

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.

Peter Presland

Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King's College, University of London, he qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc ("Heath"), a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the Group Finance Director. He was promoted to Heath's Group Chief Executive in 1990, and in 1996 led the demerger of Heath's computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Chairman. Since 2001, Peter has pursued a portfolio non-executive career, becoming Chairman of a number of IT and financial services companies, including LINK, the UK ATM network, in 2003 where he led a major corporate governance change as well as the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. Among other appointments, from 2012 to 2015, he served as Chairman of the Audit & Governance Committee of East Kent Hospitals NHS Trust, in 2017 was appointed to the board of Redx Pharma PLC, and in 2019 was asked to become Chairman of the Governance & Finance Committee of the Lord's Taverners, a high-profile charity.

Peter joined the Board in March 2025. He chairs the Audit Committee and sits on the Remuneration and Nomination committees.